Stock NRIX NURIX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-16 pm EDT 		5-day change 1st Jan Change
15.4 USD -3.14% Intraday chart for Nurix Therapeutics, Inc. +10.39% +49.22%
May. 14 Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target MT
Apr. 12 Sector Update: Health Care Stocks Steady Pre-Bell Friday MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
AQ
Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target
MT
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
AQ
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
AQ
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
AQ
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Sector Update: Health Care
MT
North American Morning Briefing : Big Banks Kick off Earnings Season
DJ
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share
MT
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
AQ
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours
MT
Nurix Therapeutics Announces Proposed Public Offering
AQ
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating
MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier
MT
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024
CI
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
AQ
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M
MT
North American Morning Briefing : Traders Await -2-
DJ
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
DJ
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRIX Stock
  4. News Nurix Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW